Adult acute megakaryocytic leukemia: An analysis of 37 patients treated at M.D. Anderson Cancer Center

Yasuhiro Oki, Hagop M. Kantarjian, Xian Zhou, Jorge Cortes, Stefan Faderl, Srdan Verstovsek, Susan O'Brien, Charles Koller, Miloslav Beran, B. Nebiyou Bekele, Sherry Pierce, Deborah Thomas, Farhad Ravandi, William G. Wierda, Francis Giles, Alessandra Ferrajoli, Elias Jabbour, Michael J. Keating, Carlos E. Bueso-Ramos, Elihu EsteyGuillermo Garcia-Manero

Research output: Contribution to journalArticle

Abstract

To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D. Anderson Cancer Center between 1987 and 2003 and compared them with 1800 patients with non-M7, non-M3AML-treated during the same period. The median age of the M7 AML group was 56 years (range, 21-78 years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both, and 7 patients (19%) had previously received chemotherapy for other malignancies. Extensive bone marrow fibrosis was found in 23 patients (62%). Poor cytogenetic characteristics were observed in 49% of patients with M7 AML versus 33% of others (P < .001). Complete remission rates were 43% with M7 AML and 57% with non-M7 AML (P = .089). Median overall survival (OS) was 23 and 38 weeks, respectively (P = .006). Median disease-free survivals were 23 versus 52 weeks, respectively (P < .001). By multivariate analysis, M7 AML was an independent adverse prognostic factor for OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, P = .049). These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.

Original languageEnglish (US)
Pages (from-to)880-884
Number of pages5
JournalBlood
Volume107
Issue number3
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

Leukemia, Megakaryoblastic, Acute
Chemotherapy
Neoplasms
Hazards
Bone
Chromosome Aberrations
Primary Myelofibrosis
Survival
Myelodysplastic Syndromes
Cytogenetics
Disease-Free Survival
Multivariate Analysis
Drug Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Oki, Y., Kantarjian, H. M., Zhou, X., Cortes, J., Faderl, S., Verstovsek, S., ... Garcia-Manero, G. (2006). Adult acute megakaryocytic leukemia: An analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood, 107(3), 880-884. https://doi.org/10.1182/blood-2005-06-2450

Adult acute megakaryocytic leukemia : An analysis of 37 patients treated at M.D. Anderson Cancer Center. / Oki, Yasuhiro; Kantarjian, Hagop M.; Zhou, Xian; Cortes, Jorge; Faderl, Stefan; Verstovsek, Srdan; O'Brien, Susan; Koller, Charles; Beran, Miloslav; Bekele, B. Nebiyou; Pierce, Sherry; Thomas, Deborah; Ravandi, Farhad; Wierda, William G.; Giles, Francis; Ferrajoli, Alessandra; Jabbour, Elias; Keating, Michael J.; Bueso-Ramos, Carlos E.; Estey, Elihu; Garcia-Manero, Guillermo.

In: Blood, Vol. 107, No. 3, 01.02.2006, p. 880-884.

Research output: Contribution to journalArticle

Oki, Y, Kantarjian, HM, Zhou, X, Cortes, J, Faderl, S, Verstovsek, S, O'Brien, S, Koller, C, Beran, M, Bekele, BN, Pierce, S, Thomas, D, Ravandi, F, Wierda, WG, Giles, F, Ferrajoli, A, Jabbour, E, Keating, MJ, Bueso-Ramos, CE, Estey, E & Garcia-Manero, G 2006, 'Adult acute megakaryocytic leukemia: An analysis of 37 patients treated at M.D. Anderson Cancer Center', Blood, vol. 107, no. 3, pp. 880-884. https://doi.org/10.1182/blood-2005-06-2450
Oki, Yasuhiro ; Kantarjian, Hagop M. ; Zhou, Xian ; Cortes, Jorge ; Faderl, Stefan ; Verstovsek, Srdan ; O'Brien, Susan ; Koller, Charles ; Beran, Miloslav ; Bekele, B. Nebiyou ; Pierce, Sherry ; Thomas, Deborah ; Ravandi, Farhad ; Wierda, William G. ; Giles, Francis ; Ferrajoli, Alessandra ; Jabbour, Elias ; Keating, Michael J. ; Bueso-Ramos, Carlos E. ; Estey, Elihu ; Garcia-Manero, Guillermo. / Adult acute megakaryocytic leukemia : An analysis of 37 patients treated at M.D. Anderson Cancer Center. In: Blood. 2006 ; Vol. 107, No. 3. pp. 880-884.
@article{671f7271df0249ed82a66420f7ac2ace,
title = "Adult acute megakaryocytic leukemia: An analysis of 37 patients treated at M.D. Anderson Cancer Center",
abstract = "To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D. Anderson Cancer Center between 1987 and 2003 and compared them with 1800 patients with non-M7, non-M3AML-treated during the same period. The median age of the M7 AML group was 56 years (range, 21-78 years); 22 patients (59{\%}) had an antecedent hematologic disorder or myelodysplastic syndrome or both, and 7 patients (19{\%}) had previously received chemotherapy for other malignancies. Extensive bone marrow fibrosis was found in 23 patients (62{\%}). Poor cytogenetic characteristics were observed in 49{\%} of patients with M7 AML versus 33{\%} of others (P < .001). Complete remission rates were 43{\%} with M7 AML and 57{\%} with non-M7 AML (P = .089). Median overall survival (OS) was 23 and 38 weeks, respectively (P = .006). Median disease-free survivals were 23 versus 52 weeks, respectively (P < .001). By multivariate analysis, M7 AML was an independent adverse prognostic factor for OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, P = .049). These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.",
author = "Yasuhiro Oki and Kantarjian, {Hagop M.} and Xian Zhou and Jorge Cortes and Stefan Faderl and Srdan Verstovsek and Susan O'Brien and Charles Koller and Miloslav Beran and Bekele, {B. Nebiyou} and Sherry Pierce and Deborah Thomas and Farhad Ravandi and Wierda, {William G.} and Francis Giles and Alessandra Ferrajoli and Elias Jabbour and Keating, {Michael J.} and Bueso-Ramos, {Carlos E.} and Elihu Estey and Guillermo Garcia-Manero",
year = "2006",
month = "2",
day = "1",
doi = "10.1182/blood-2005-06-2450",
language = "English (US)",
volume = "107",
pages = "880--884",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Adult acute megakaryocytic leukemia

T2 - An analysis of 37 patients treated at M.D. Anderson Cancer Center

AU - Oki, Yasuhiro

AU - Kantarjian, Hagop M.

AU - Zhou, Xian

AU - Cortes, Jorge

AU - Faderl, Stefan

AU - Verstovsek, Srdan

AU - O'Brien, Susan

AU - Koller, Charles

AU - Beran, Miloslav

AU - Bekele, B. Nebiyou

AU - Pierce, Sherry

AU - Thomas, Deborah

AU - Ravandi, Farhad

AU - Wierda, William G.

AU - Giles, Francis

AU - Ferrajoli, Alessandra

AU - Jabbour, Elias

AU - Keating, Michael J.

AU - Bueso-Ramos, Carlos E.

AU - Estey, Elihu

AU - Garcia-Manero, Guillermo

PY - 2006/2/1

Y1 - 2006/2/1

N2 - To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D. Anderson Cancer Center between 1987 and 2003 and compared them with 1800 patients with non-M7, non-M3AML-treated during the same period. The median age of the M7 AML group was 56 years (range, 21-78 years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both, and 7 patients (19%) had previously received chemotherapy for other malignancies. Extensive bone marrow fibrosis was found in 23 patients (62%). Poor cytogenetic characteristics were observed in 49% of patients with M7 AML versus 33% of others (P < .001). Complete remission rates were 43% with M7 AML and 57% with non-M7 AML (P = .089). Median overall survival (OS) was 23 and 38 weeks, respectively (P = .006). Median disease-free survivals were 23 versus 52 weeks, respectively (P < .001). By multivariate analysis, M7 AML was an independent adverse prognostic factor for OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, P = .049). These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.

AB - To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D. Anderson Cancer Center between 1987 and 2003 and compared them with 1800 patients with non-M7, non-M3AML-treated during the same period. The median age of the M7 AML group was 56 years (range, 21-78 years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both, and 7 patients (19%) had previously received chemotherapy for other malignancies. Extensive bone marrow fibrosis was found in 23 patients (62%). Poor cytogenetic characteristics were observed in 49% of patients with M7 AML versus 33% of others (P < .001). Complete remission rates were 43% with M7 AML and 57% with non-M7 AML (P = .089). Median overall survival (OS) was 23 and 38 weeks, respectively (P = .006). Median disease-free survivals were 23 versus 52 weeks, respectively (P < .001). By multivariate analysis, M7 AML was an independent adverse prognostic factor for OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, P = .049). These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.

UR - http://www.scopus.com/inward/record.url?scp=31544447448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544447448&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-06-2450

DO - 10.1182/blood-2005-06-2450

M3 - Article

C2 - 16123215

AN - SCOPUS:31544447448

VL - 107

SP - 880

EP - 884

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -